Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824358 | 0.78 | — | — | |
| SCHEMBL125451 | 0.72 | — | — | |
| SCHEMBL27492784 | 0.72 | ALDH1A1 (0.37) | ALDH1A1DPP4CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL12339807 | 0.72 | ALDH1A1 (0.34) | ALDH1A1DPP4CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL38655959 | 0.71 | MEN1 (0.35) | ALDH1A1DPP4CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL4325866 | 0.71 | ALDH1A1 (0.37) | ALDH1A1DPP4CYP2E1CYP3A4CYP2A6 | |
| 2,5-Thiophenenedicarboxaldehyde SCHEMBL178830 | 0.69 | — | — | |
| SCHEMBL31427498 | 0.68 | CES2 (0.37) | — | |
| SCHEMBL178042 | 0.68 | TSHR (0.46) | ALDH1A1DPP4CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL28979724 | 0.68 | DAO (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504701-A | Novel fluorescent probe based on triphenylamine and preparation method and application thereof | 广东医科大学 | 2025-02-25 | — | — | CN | claimed |
| CN-114195774-B | Photosensitizer with hypochlorous acid activated fluorescence and mitochondrial targeting functions and preparation method and application thereof | 徐州医科大学 | 2023-09-26 | — | — | CN | claimed |
| CN-114609102-B | Method for in-situ monitoring polymer film forming process by using fluorescent probe | 四川大学 | 2023-07-28 | — | — | CN | claimed |
| CN-114609102-A | Method for in-situ monitoring of polymer film forming process by using fluorescent probe | 四川大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114195774-A | Photosensitizer with hypochlorous acid activated fluorescence and mitochondrion targeting functions and preparation method and application thereof | 徐州医科大学 | 2022-03-18 | — | — | CN | claimed |
| CN-122031387-A | Diagnosis and treatment integrated viscosity response self-assembled nano micelle and preparation method and application thereof | 山西医科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122042081-A | Ratio type fluorescent nano thermometer based on temperature response type amphiphilic polymer and preparation and application thereof | 西安交通大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-119504701-B | Novel fluorescent probe based on triphenylamine and preparation method and application thereof | 广东医科大学 | 2025-10-03 | — | — | CN | disclosed |
| CN-119504701-A | Novel fluorescent probe based on triphenylamine and preparation method and application thereof | 广东医科大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-119504701-A | Novel fluorescent probe based on triphenylamine and preparation method and application thereof | 广东医科大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-114195774-B | Photosensitizer with hypochlorous acid activated fluorescence and mitochondrial targeting functions and preparation method and application thereof | 徐州医科大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-111892592-B | JAK kinase inhibitors and uses thereof | 江苏柯菲平医药股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3124482-B1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-09-11 | — | — | EP | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| EP-3124482-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-02-01 | — | — | EP | disclosed |
| US-7425563-B2 | Excellent poly (ADP-ribose) synthetase inhibitors; various ischemic diseases, inflammatory diseases, neurodegenerative diseases, diabetes, septic shock, cephalic injury; 1,2-Dihydro-4-[4-(dimethylaminomethyl)phenyl]-5-hydroxy-1-oxoisoquinoline | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20060173039-A1 | 4-(Substituted aryl)-5-hydroxyisoquinolinone derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1544194-A1 | 4-(SUBSTITUTED ARYL)-5-HYDROXYISOQUINOLINONE DERIVATIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173039-A1 | 4-(Substituted aryl)-5-hydroxyisoquinolinone derivative | PARP1, PARP11, PARP4 | ALDH1A1 58/4885DPP4 110/4885CYP2E1 1474/4885 |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | ALDH1A1 3363/4885DPP4 550/4885CYP2E1 2129/4885 |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | ALDH1A1 892/4885DPP4 3025/4885CYP2E1 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.